Peer-reviewed veterinary case report
Outcome of lymphoma treatment in dogs using single vs divided
By Lee, Jih-Jong et al.·Published in Topics in companion animal medicine·2020·Graduate Institute of Veterinary Clinical Science·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Outcome of Canine Multicentric Lymphoma after Single or Divided Treatment with Cyclophosphamide in Multidrug Chemotherapy.
- Species:
- dog
Plain-English summary
A group of 72 dogs with lymphoma received either single or divided doses of a chemotherapy drug called cyclophosphamide. While the divided doses were thought to potentially reduce bladder irritation and bleeding (a side effect known as hemorrhagic cystitis), the study found no significant difference in the occurrence of this side effect between the two treatment methods. Additionally, both groups had similar outcomes in terms of how long they lived and how well they responded to treatment. This means that splitting the doses did not help reduce side effects or improve survival for dogs with lymphoma.
People also search for: dog lymphoma treatment options · cyclophosphamide side effects in dogs · dog chemotherapy bladder problems
Abstract
Cyclophosphamide is commonly used in combination chemotherapy to treat dogs with lymphoma. The metabolite of cyclophosphamide, acrolein, can irritate urinary bladder and cause sterile hemorrhagic cystitis. Dividing the administration of cyclophosphamide across multiple days may reduce the concentration of this metabolite in urinary bladder and reduce the possibility of cystitis. However, the impact of the therapeutic effect of this modification is not evaluated and compared to traditional single maximum-tolerated dose regimen. Seventy-two dogs with multicentric lymphoma received either bolus doses or divided doses of cyclophosphamide were included in this study. The incidence of hemorrhagic cystitis between 2 cyclophosphamide treatment groups was not significantly different (P = .357). There was no statistical difference in progression-free survival and survival time between 2 groups (P = .267 and P = .346). This modification of cyclophosphamide administration did not reduce the side effect of cystitis or affect remission and survival times in lymphoma dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32823160/